Boosting Psoriasis Outcomes with a Dual Strategy – Deucravacitinib Plus Calcipotriene/Betamethasone Foam Shows Lasting Benefits
A promising new open-label study in our August issue highlights how adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib can amplify clearance and quality-of-life gains for adults with moderate to severe chronic plaque psoriasis. Thirty patients began deucravacitinib 6 mg daily. By week 8, five patients had achieved PASI 75 and continued on deucravacitinib alone through week 24. Twenty patients with partial responses (PASI 25–74) received daily C/BD foam for four weeks, resulting in remarkable additional improvements by week 12: an 83% further PASI reduction, 52% drop in PGA scores, 78% decrease in BSA involvement, and a 74% boost in DLQI. These gains remained stable up to week 24. Only mild adverse events were reported, and none led to treatment discontinuation.
This study underscores the synergy of targeted TYK2 inhibition with localized anti-inflammatory therapy. Dermatologists seeking to optimize clearance and enhance patient satisfaction should consider C/BD foam rescue for partial responders on deucravacitinib. As safety and durability of effect are paramount, these real-world data pave the way for personalized, combination-based psoriasis protocols.
Don’t miss the full details—explore how this dual approach could redefine your plaque psoriasis treatment algorithm and elevate patient outcomes today.
J Drugs Dermatol (2025;24(8): doi:10.36849/JDD.8955)
Blog write-up assisted by AI
